SBI Securities Co. Ltd. Invests $7.73 Million in Pfizer Inc. (NYSE:PFE)

SBI Securities Co. Ltd. bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 291,381 shares of the biopharmaceutical company’s stock, valued at approximately $7,730,000.

A number of other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp raised its position in shares of Pfizer by 36.3% during the fourth quarter. Jones Financial Companies Lllp now owns 1,825,952 shares of the biopharmaceutical company’s stock worth $48,442,000 after purchasing an additional 485,895 shares during the period. SRS Capital Advisors Inc. raised its position in shares of Pfizer by 299.8% during the fourth quarter. SRS Capital Advisors Inc. now owns 38,977 shares of the biopharmaceutical company’s stock worth $1,034,000 after purchasing an additional 29,229 shares during the period. Clifford Swan Investment Counsel LLC raised its position in shares of Pfizer by 8.5% during the fourth quarter. Clifford Swan Investment Counsel LLC now owns 601,624 shares of the biopharmaceutical company’s stock worth $15,961,000 after purchasing an additional 47,279 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter valued at $28,000. Finally, Hickory Point Bank & Trust purchased a new stake in Pfizer in the 4th quarter valued at $459,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 1.3 %

Shares of PFE opened at $26.43 on Friday. The business has a 50-day moving average of $26.35 and a 200 day moving average of $27.33. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm has a market cap of $149.78 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.51%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Finally, Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.